Purging of murine erythroblastic leukemia by ZnPcS2 P2-based-photodynamic therapy

Bone Marrow Transplantation

Volumn 37, Issue 2, 2006, Pages 213-217

  Huang, H F ^a   Chen, Y Z ^a   Wu, Y ^a   Chen, P ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Bone marrow; Photodynamic therapy; Purging; Zinc phthalocyanine

Indexed keywords

DISULFODIPHTHALIMIDOMETHYLPHTHALOLCYANINE ZINC; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; ERYTHROLEUKEMIA; FEMALE; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; WHOLE BODY RADIATION;

ANIMALS; BONE MARROW PURGING; CELL LINE, TUMOR; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INDOLES; LEUKEMIA, MYELOID; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; ORGANOMETALLIC COMPOUNDS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; TRANSPLANTATION, AUTOLOGOUS;

EID: 30944470078     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705216     Document Type: Article

References (25)

1. Jamieson CH, McDonald WN, Levy JG. Preferential uptake of benzoporphyrin derivative by leukemic versus normal cells. Leuk Res 1990; 14: 209-219.
2. Lydaki E, Dimitriou H, Papazoglou T, Liu WQ, Kalmanti M. Merocyanine 540 mediated photolysis of normal bone marrow, committed hemopoietic progenitors and neoplastic cells. Implications for bone marrow purging. Leuk Res 1997; 21: 641-650.
3. Danilatou V, Lydaki E, Dimitriou H, Papazoglou T, Kalmanti M. Bone marrow purging by photodynamic treatment in children with acute leukemia: Cytoprotective action of amifostine. Leuk Res 2000; 24: 427-435.
4. Gluckman E, Rocha V, Arcese W, Michel G, Sanz G, Chan KW et al. Factors associated with outcomes of unrelated cord blood transplant: Guidelines for donor choice. Exp Hematol 2004; 32: 397-407.
5. Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D et al. Genetic marking shows that ph + cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068-3076.
6. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro Jr J, Anderson WF et al. Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 1993; 341: 85-86.
7. Gautam SC, Xu YX, Dumaguin M, Janakiraman N, Chapman RA. Resveratrol selectively inhibits leukemia cells: A prospective agent for ex vivo bone marrow purging. Bone Marrow Transplant 2000; 25: 639-645.
8. Garcia-Castro J, Rio P, Lillo R, Garcia-Sanchez F, Segovia JC, Bueren JA. Purging of leukemia-contaminated bone marrow grafts using suicide adenoviral vectors: An in vivo murine experimental model. Gene Therapy 2003; 10: 1328-1335.
9. 3. Br J Haematol 2000; 111: 1145-1152.
10. Garcia-Castro J, Segovia JC, Bueren JA. Transplantation of syngenic bone marrow contaminated with NGFr-marked WEHI-3B cells: An improved model of leukemia relapse in mice. Leukemia 2000; 14: 457-465.
11. Kuhl JS, Sikic BI, Blume KG, Chao NJ. Use of etoposide in combination with cyclosporin for purging multidrug-resistant leukemic cells from bone marrow in a mouse model. Exp Hematol 1992; 20: 1048-1054.
12. Long GS, Hiserodt JC, Harnaha JB, Cramer DV. Lymphokine-activated killer cell purging of leukemia cells from bone marrow prior to syngeneic transplantation. Transplantation 1988; 46: 433-438.
13. Niedre M, Patterson MS, Wilson BC. Direct near-infrared luminescence detection of singlet oxygen generated by photodynamic therapy in cells in vitro and tissues in vivo. Photochem photobiol 2002; 75: 382-391.
14. Granville DJ, Carthy CM, Jiang H, Levy JG, McManus BM, Matroule JY et al. Nuclear factor-kB activation by the photochemotherapeutic agent verteporfin. Blood 2000; 95: 256-262.
15. Casas A, Fukuda H, Venosa GD, Batlle A. Photosensitization and mechanism of cytotoxicity induced by the use of ALA derivatives in photodynamic therapy. Br J Cancer 2001; 85: 279-284.
16. Villeneuve L. Ex vivo photodynamic purging in chronic myelogenous leukaemia and other neoplasias with rhodamine derivatives. Biotechnol Appl Biochem 1999; 30: 1-17.
17. Daziano JP, Humeau L, Henry M, Mannoni P, Chanon M, Chabannon C et al. Preferential photoinactivation of leukemia cells by aluminum phthalocyanine. J Photochem Photobiol B 1998; 43: 128-135.
18. Yamazaki T, Sato Y, Sieber F. Role of cytoprotective mechanisms in the photochemical purging of autologous bone marrow grafts. Exp Hematol 1997; 25: 629-637.
19. Yamazaki T, Sieber F. The alkyl-lysophospholipid, ET-18-OCH3 synergistically enhances the Merocyanine 540-mediated photoinactivation of leukemia cells: Implications for the extracorporeal purging of autologous hematopoietic stem cells. Bone Marrow Transplant 1997; 19: 113-119.
20. Singer CR, Linch DC, Bown SG, Huehns ER, Goldstone AH. Differential phthalocyanine photosensitization of acute myeloblastic leukaemia progenitor cells: A potential purging technique for autologous bone marrow transplantation. Br J Haematol 1988; 68: 417-422.
21. Huang HF, Chen YZ, Wu Y. Experimental studies of the effects of ZnPcS2P2 -based-photodynamic therapy on bone marrow purging. Chin Med J 2005; 118: 105-110.
22. Huang JL, Chen NS, Huang JD, Liu ES, Xue JP, Yang SL et al. Metal phthalocyanine as photosensitizer for photodynamic therapy (PDT). Sci China (Series B) 2001; 44: 113-122.
23. Ding SL, Chu JX, Zhao JM. Establishment and biological characterization of transplantable BALB/c mouse erythroblastic leukemia model. China J Hematol (China) 1998; 19: 638-641.
24. Gidali J, Feher I. The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells. Bone Marrow Transplant 1992; 10: 479-483.
25. Rousset N, Vonarx V, Eleouet S, Carre J, Bourre L, Lajat Y et al. Cellular distribution and phototoxicity of benzoporphyrin derivative and photofrin. Res Exp Med (Berlin 1) 2000; 199: 341-357.